Cargando…
Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?
OBJECTIVES: We critically evaluated the quality of evidence and quality of harm reporting in clinical trials that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of coronavirus disease 2019 (COVID-19). STUDY DESIGN AND SETTING: Scientific databases were...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524513/ https://www.ncbi.nlm.nih.gov/pubmed/33007453 http://dx.doi.org/10.1016/j.ijid.2020.09.1470 |
_version_ | 1783588555284545536 |
---|---|
author | Mazhar, Faizan Hadi, Muhammad Abdul Kow, Chia Siang Marran, Albaraa Mohammed N. Merchant, Hamid A. Hasan, Syed Shahzad |
author_facet | Mazhar, Faizan Hadi, Muhammad Abdul Kow, Chia Siang Marran, Albaraa Mohammed N. Merchant, Hamid A. Hasan, Syed Shahzad |
author_sort | Mazhar, Faizan |
collection | PubMed |
description | OBJECTIVES: We critically evaluated the quality of evidence and quality of harm reporting in clinical trials that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of coronavirus disease 2019 (COVID-19). STUDY DESIGN AND SETTING: Scientific databases were systematically searched to identify relevant trials of HCQ/CQ for the treatment of COVID-19 published up to 10 September 2020. The Cochrane risk-of-bias tools for randomized trials and non-randomized trials of interventions were used to assess risk of bias in the included studies. A 10-item Consolidated Standards of Reporting Trials (CONSORT) harm extension was used to assess quality of harm reporting in the included trials. RESULTS: Sixteen trials, including fourteen randomized trials and two non-randomized trials, met the inclusion criteria. The results from the included trials were conflicting and lacked effect estimates adjusted for baseline disease severity or comorbidities in many cases, and most of the trials recruited a fairly small cohort of patients. None of the clinical trials met the CONSORT criteria in full for reporting harm data in clinical trials. None of the 16 trials had an overall ‘low’ risk of bias, while four of the trials had a ‘high’, ‘critical’, or ‘serious’ risk of bias. Biases observed in these trials arise from the randomization process, potential deviation from intended interventions, outcome measurements, selective reporting, confounding, participant selection, and/or classification of interventions. CONCLUSION: In general, the quality of currently available evidence for the effectiveness of CQ/HCQ in patients with COVID-19 is suboptimal. The importance of a properly designed and reported clinical trial cannot be overemphasized amid the COVID-19 pandemic, and its dismissal could lead to poorer clinical and policy decisions, resulting in wastage of already stretched invaluable health care resources. |
format | Online Article Text |
id | pubmed-7524513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75245132020-09-30 Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? Mazhar, Faizan Hadi, Muhammad Abdul Kow, Chia Siang Marran, Albaraa Mohammed N. Merchant, Hamid A. Hasan, Syed Shahzad Int J Infect Dis Review OBJECTIVES: We critically evaluated the quality of evidence and quality of harm reporting in clinical trials that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of coronavirus disease 2019 (COVID-19). STUDY DESIGN AND SETTING: Scientific databases were systematically searched to identify relevant trials of HCQ/CQ for the treatment of COVID-19 published up to 10 September 2020. The Cochrane risk-of-bias tools for randomized trials and non-randomized trials of interventions were used to assess risk of bias in the included studies. A 10-item Consolidated Standards of Reporting Trials (CONSORT) harm extension was used to assess quality of harm reporting in the included trials. RESULTS: Sixteen trials, including fourteen randomized trials and two non-randomized trials, met the inclusion criteria. The results from the included trials were conflicting and lacked effect estimates adjusted for baseline disease severity or comorbidities in many cases, and most of the trials recruited a fairly small cohort of patients. None of the clinical trials met the CONSORT criteria in full for reporting harm data in clinical trials. None of the 16 trials had an overall ‘low’ risk of bias, while four of the trials had a ‘high’, ‘critical’, or ‘serious’ risk of bias. Biases observed in these trials arise from the randomization process, potential deviation from intended interventions, outcome measurements, selective reporting, confounding, participant selection, and/or classification of interventions. CONCLUSION: In general, the quality of currently available evidence for the effectiveness of CQ/HCQ in patients with COVID-19 is suboptimal. The importance of a properly designed and reported clinical trial cannot be overemphasized amid the COVID-19 pandemic, and its dismissal could lead to poorer clinical and policy decisions, resulting in wastage of already stretched invaluable health care resources. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020-12 2020-09-29 /pmc/articles/PMC7524513/ /pubmed/33007453 http://dx.doi.org/10.1016/j.ijid.2020.09.1470 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Mazhar, Faizan Hadi, Muhammad Abdul Kow, Chia Siang Marran, Albaraa Mohammed N. Merchant, Hamid A. Hasan, Syed Shahzad Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
title | Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
title_full | Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
title_fullStr | Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
title_full_unstemmed | Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
title_short | Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
title_sort | use of hydroxychloroquine and chloroquine in covid-19: how good is the quality of randomized controlled trials? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524513/ https://www.ncbi.nlm.nih.gov/pubmed/33007453 http://dx.doi.org/10.1016/j.ijid.2020.09.1470 |
work_keys_str_mv | AT mazharfaizan useofhydroxychloroquineandchloroquineincovid19howgoodisthequalityofrandomizedcontrolledtrials AT hadimuhammadabdul useofhydroxychloroquineandchloroquineincovid19howgoodisthequalityofrandomizedcontrolledtrials AT kowchiasiang useofhydroxychloroquineandchloroquineincovid19howgoodisthequalityofrandomizedcontrolledtrials AT marranalbaraamohammedn useofhydroxychloroquineandchloroquineincovid19howgoodisthequalityofrandomizedcontrolledtrials AT merchanthamida useofhydroxychloroquineandchloroquineincovid19howgoodisthequalityofrandomizedcontrolledtrials AT hasansyedshahzad useofhydroxychloroquineandchloroquineincovid19howgoodisthequalityofrandomizedcontrolledtrials |